JYMed yakapihwa patent yeEuropean patent yayo yekuvandudza nzira yeLiraglutide. Ichi chiitiko chinoratidza kuenderera kwedu hutungamiriri mu peptide R&D uye IP. Iyi patent inomiririra maitiro matsva ekugadzira liraglutide, iyo isingangove yakagadzikana goho asi zvakare inoderedza zvakanyanya kuumbwa kweiyo racemic tsvina [D-Thr ^ 5] -Liraglutide, iyo inofanana neyakagadzirirwa chigadzirwa. Ichi chitsva chinowedzera kunaka kwechigadzirwa.

Kutorwa kweiyi European patent kunoratidza kugona kwakazara kweR&D kwekambani, ichiwedzera kusimbisa zvakanakira tekinoroji. Inobatsira kusimbisa kukwikwidza kweJYMed uye kuwedzera kuvepo kwayo mumisika yepasirese. Pamusoro pezvo, inosimbisa kunaka kwekambani yehungwaru, kubatsira kuchengetedza nekusimudzira kukwikwidza kwayo kwemusika wepasi rose.

Hubei JXBio Pharmaceutical Co., Ltd, inotsigira Shenzhen JYMed Technology Co., Ltd, ichangobva kugamuchira Market Approval Notification yeOxytocin Active Pharmaceutical Ingredient (API) yakapihwa neNational Medical Products Administration (NMPA) yekuChina.

Mvumo iyi inoratidza kuti JXBio's oxytocin API inosangana nezvinodiwa zvetekinoroji zvakatarwa nehurongwa hwekuongorora mishonga yenyika. Inotaridza chiitiko chakakosha kukambani, ichiwedzera kupfumisa chigadzirwa chayo uye nekupa hwaro hwakasimba hwekuwedzera kwemusika muchikamu cheoxytocin.
ABOUT JYMED
JYMed ikambani yepamusoro-tech biopharmaceutical kambani inoshanda mukutsvagisa yakazvimirira, kusimudzira, kugadzira, uye kutengesa peptide-based zvigadzirwa, pamwe nekuvandudza kondirakiti uye kugadzira sangano (CDMO) masevhisi. Iyo kambani yakazvipira kupa emhando yepamusoro peptide APIs uye yakagadziridzwa mhinduro kune vatengi vepasirese. Yayo chigadzirwa portfolio inosanganisira akawanda epeptide APIs, ane zvakakosha zvigadzirwa seSemaglutide uye Terlipressin atopedza US FDA DMF mafiling.

Chikamu chayo cheHubei JXBio Pharmaceutical Co., Ltd., inoshandisa mitsetse yekugadzirwa kwepeptide API inofambirana neCGMP zviyero zvakatarwa neUS FDA, European EMA, uye NMPA yekuChina. Nzvimbo iyi inosanganisira gumi mikuru uye mitsetse yekugadzira yekutyaira uye yakagadzira yakaomesesa pharmaceutical quality management system (QMS) uye hutano hwezvakatipoteredza nekuchengetedza (EHS) manejimendi system. Izvi zvinovimbisa kuti maitiro ese, kubva kuR&D kusvika pakugadzirwa, anosangana nepamusoro-soro mwero wepasirese. Iyo kambani yakabudirira kupasa GMP kutevedza ongororo neUS FDA neChina's NMPA uye yakazivikanwa nemakambani anotungamira emishonga epasi rose nekuda kweEHS manejimendi, ichiratidza kuzvipira kwayo kumhando, chengetedzo, uye basa rezvakatipoteredza.

Core Business Nzvimbo:Zvemukati uye zvepasi rose peptide API kunyoreswa uye kutevedzera,Veterinary uye cosmetic peptides,Tsika peptide masevhisi, anosanganisira CRO, CMO, uye OEM mhinduro,Peptide-zvinodhaka conjugates (PDCs), kusanganisira peptide-radionuclide, peptide-diki molecule, peptide-protein, uye peptide-RNA therapeutics..

MAIN PRODUCTS

Kuti uwane mamwe mashoko pamusoro pezvigadzirwa zvedu, tapota taura nesu.

Global API uye Zvizoro Mibvunzo: Tel Nha.: +86-15013529272;

API Kunyoresa & CDMO Services (USA EU musika）: +86-15818682250

E-mail:jymed@jymedtech.com

Kero: Floors 8 & 9, Building 1, Shenzhen Biomedical Innovation Industrial Park, 14 Jinhui Road, Kengzi Subdistrict, Pingshan District, Shenzhen